Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
Type:
Grant
Filed:
June 21, 2021
Date of Patent:
April 30, 2024
Assignee:
GENMAB A/S
Inventors:
David Satijn, Esther C. W. Breij, Bart E. C. G. De Goeij, Kristel Kemper, Patrick Engelberts, Edward N. Van Den Brink, Rik Rademaker, Dennis Verzijl, Sjeng Horbach, Paul Parren
Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
Type:
Grant
Filed:
June 28, 2021
Date of Patent:
March 26, 2024
Assignees:
GENMAB A/S, BioNTech SE
Inventors:
Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Friederike Gieseke, Ugur Sahin
Abstract: The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.
Type:
Grant
Filed:
May 11, 2023
Date of Patent:
March 19, 2024
Assignees:
BioNTech SE, Genmab A/S
Inventors:
Ugur Sahin, Sina Fellermeier-Kopf, Friederike Gieseke, Karsten Beckmann, Claudia Paulmann, Alexander Muik, Ivan Kuzmanov, Esther Cornelia Wilhelmina Breij, Patricia Garrido Castro, Jordan Blum, Lars Guelen, Joost Neijssen, Bart-Jan De Kreuk, Richard Hibbert, Janine Schuurman, Aran Frank Labrijn
Abstract: Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.
Type:
Grant
Filed:
January 30, 2020
Date of Patent:
January 9, 2024
Assignee:
GENMAB A/S
Inventors:
Aran Frank Labrijn, Joyce I. Meesters, Ewald T. J. Van Den Bremer, Joost J. Neijssen, Patrick Van Berkel, Bart De Goeij, Tom Vink, Jan Van De Winkel, Janine Schuurman, Paul Parren
Abstract: Provided are methods of clinical treatment of chronic lymphoblastic leukemia (CLL) in human subjects using a bispecific antibody which binds to CD3 and CD20.
Type:
Grant
Filed:
December 22, 2021
Date of Patent:
January 2, 2024
Assignee:
GENMAB A/S
Inventors:
Brian Elliott, Jenny Jianlin Chen, Tahamtan Ahmadi, Christopher W. L. Chiu, Esther C. W. Breij, Ida Hiemstra, Maria N. Jure-Kunkel
Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
Type:
Grant
Filed:
December 21, 2021
Date of Patent:
December 19, 2023
Assignee:
GENMAB A/S
Inventors:
Brian Elliott, Tahamtan Ahmadi, Christopher W. L. Chiu, Esther C. W Breij, Ida Hiemstra, Maria N. Jure-Kunkel
Abstract: The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.
Type:
Grant
Filed:
October 6, 2022
Date of Patent:
November 14, 2023
Assignee:
GENMAB A/S
Inventors:
David Satijn, Patrick Engelberts, Kristel Kemper, Esther C. W. Breij, Simone Oostindie, Farshid Alemdehy
Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
Type:
Grant
Filed:
January 8, 2021
Date of Patent:
November 14, 2023
Assignees:
BIONTECH SE, GENMAB A/S
Inventors:
Ugur Sahin, Friederike Gieseke, Isil Altintas, David Satijn, Paul Parren
Abstract: Antibody variants having decreased or increased ability to mediate CDC due to modifications at the C-terminus of their heavy chains are described. Methods of generating such antibodies, as well as nucleotide constructs and host cells suitable for the production of said antibodies are also described.
Type:
Grant
Filed:
April 30, 2019
Date of Patent:
October 24, 2023
Assignee:
GENMAB A/S
Inventors:
Paul Parren, Patrick Van Berkel, Ewald Van Den Bremer
Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
Type:
Grant
Filed:
August 19, 2019
Date of Patent:
March 28, 2023
Assignee:
GENMAB A/S
Inventors:
Edward Norbert Van Den Brink, Joost J. Neijssen, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Isil Altintas, Paul Parren, Rik Rademaker
Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.
Type:
Grant
Filed:
December 22, 2021
Date of Patent:
March 21, 2023
Assignee:
GENMAB A/S
Inventors:
Brian Elliott, Tahamtan Ahmadi, Christopher W. L. Chiu, Esther C. W. Breij, Ida Hiemstra, Maria N. Jure-Kunkel
Abstract: Bispecific antibodies which comprise one antigen-binding region binding to an epitope of human epidermal growth factor receptor 2 (HER2) and one antigen-binding region binding to human CD3, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods for preparing and using the antibodies are also disclosed.
Type:
Grant
Filed:
October 29, 2019
Date of Patent:
February 14, 2023
Assignee:
GENMAB A/S
Inventors:
Joost J. Neijssen, Joyce I. Meesters, Bart De Goeij, Aran Frank Labrijn, Paul Parren, Janine Schuurman
Abstract: The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.
Type:
Application
Filed:
November 6, 2020
Publication date:
January 26, 2023
Applicants:
Genmab A/S, MSD International GmbH
Inventors:
Reshma Abdulla RANGWALA, Esther C.W. BREIJ, Sandra VERPLOEGEN, Oyewale O. ABIDOYE, Leonardo Viana NICACIO, Anthony CAO, Shyra GARDAI
Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL eligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin/carboplatin).
Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and bendamustine.
Type:
Grant
Filed:
December 21, 2021
Date of Patent:
December 27, 2022
Assignee:
GENMAB A/S
Inventors:
Brian Elliott, Tahamtan Ahmadi, Christopher W. L. Chiu, Esther C. W. Breij
Abstract: The invention provides a platinum-based agent (e.g., carboplatin) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as bladder cancer and cervical cancer. The invention also provides compositions and kits comprising the platinum-based agent (e.g., carboplatin) and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as bladder cancer and cervical cancer.
Type:
Application
Filed:
November 6, 2020
Publication date:
December 8, 2022
Applicant:
Genmab A/S
Inventors:
Reshma A RANGWALA, Esther C,W. BREIJ, Sandra VERPLOEGEN, Oyewale O. ABIDOYE, Leonardo V. NICACIO
Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
Type:
Grant
Filed:
August 23, 2019
Date of Patent:
November 29, 2022
Assignee:
GENMAB A/S
Inventors:
Joost J. Neijssen, Bart De Goeij, Edward Norbert Van Den Brink, Aran Frank Labrijn, Rene Hoet, Janine Schuurman, Paul Parren, Jan Van De Winkel
Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.
Type:
Grant
Filed:
May 30, 2019
Date of Patent:
November 8, 2022
Assignee:
GENMAB A/S
Inventors:
Michael Gramer, Amitava Kundu, Ewald T. J. Van Den Bremer, Muriel Van Kampen, Patrick Priem, Aran Frank Labrijn, Joyce I. Meesters, Joost J. Neijssen, Janine Schuurman, Paul Parren, Patrick Van Berkel, Werner L. Vos, Arnout F. Gerritsen
Abstract: Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.
Type:
Grant
Filed:
February 6, 2020
Date of Patent:
November 1, 2022
Assignee:
GENMAB A/S
Inventors:
Aran Frank Labrijn, Joyce I. Meesters, Joost J. Neijssen, Edward Norbert Van Den Brink, Janine Schuurman, Paul Parren
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
Type:
Grant
Filed:
February 10, 2021
Date of Patent:
October 4, 2022
Assignees:
GENMAB A/S, BIONTECH SE
Inventors:
Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Ugur Sahin, Friederike Gieseke, Alexander Muik, Christian Grunwitz, Edward Van den Brink, Dennis Verzijl